Find Clinical Trials & Studies

Visit the Research & Education Institute

ABL103 in Combo w/ Pembrolizumab with or w/o Taxane in Solid Tumors

I'm Interested!

Please call
1-800-641-2422

A Multicenter, Open-label, Phase 1b/2 Trial of ABL103, a Bispecific Antibody of B7-H4 and 4-1BB, in Combination With Pembrolizumab With/Without Taxane in Subjects With Selected, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Solid Tumor

Study Purpose

This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.

Principal Investigator
Alberto Montero MD

Department/Division
Cancer (Any Solid Tumor)

UH IRB: STUDY20250542
StudyID: ABLB2Y25
ClinicalTrials.gov: NCT07158918

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422